Information Provided By: 
Fly News Breaks for April 10, 2015
ANGO
Apr 10, 2015 | 08:38 EDT
Canaccord said the weakness in AngioDynamics following its soft Q3 results is a buying opportunity. The firm cited negative currency impact, a slowdown in EVLT procedures, its Morpheus PICC market withdrawal, and the delay in its second generation AngioVac release. Canaccord likes the company's free cash flow generation and improved inventory management and reiterated its Buy rating, but lowered its price target to $20 from $22 on AngioDynamics shares.
News For ANGO From the Last 2 Days
There are no results for your query ANGO
